Semaglutide Clinical Trials
41 recruitingDrug
Phase 216Phase 18Phase 47Phase 37Not Applicable4
Showing 1–20 of 41 trials
Recruiting
Phase 1
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Obesity
Boehringer Ingelheim30 enrolled1 locationNCT05202353
Recruiting
Phase 2
Semaglutide Therapy for Alcohol Reduction (STAR)
Alcohol Use DisorderAddiction
National Institute on Drug Abuse (NIDA)80 enrolled1 locationNCT06015893
Recruiting
Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Novo Nordisk A/S270 enrolled63 locationsNCT07415954
Recruiting
Not Applicable
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Obesity, OverweightType 2 Diabetes (T2DM)Obesity (Disorder)
GT Metabolic Solutions, Inc.20 enrolled1 locationNCT07317115
Recruiting
Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)84 enrolled1 locationNCT03884075
Recruiting
Phase 3
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
Klinefelter Syndrome
Georgios Papadakis150 enrolled1 locationNCT05586802
Recruiting
Phase 3
Semaglutide for Smoking Cessation in Patients With Diabetes
Diabetes Mellitus, Type 2Tobacco DependenceNicotine Addiction
Ottawa Heart Institute Research Corporation100 enrolled1 locationNCT07059377
Recruiting
Phase 1
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Obesity
Novo Nordisk A/S100 enrolled1 locationNCT07527195
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Obesity
Kailera1,200 enrolled32 locationsNCT07284979
Recruiting
Phase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
ObesityOverweight
Novo Nordisk A/S460 enrolled119 locationsNCT07253285
Recruiting
Phase 4
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Obesity and Obesity-related Medical Conditions
Ali Aminian125 enrolled1 locationNCT06803888
Recruiting
Phase 2
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
Cocaine Use Disorder
The University of Texas Health Science Center, Houston75 enrolled1 locationNCT07227948
Recruiting
Phase 4
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
Prediabetes
The University of Texas Health Science Center, Houston300 enrolled1 locationNCT05119179
Recruiting
Phase 2
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
Diabetes
Mostafa Bahaa105 enrolled1 locationNCT06762314
Recruiting
Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Chronic Kidney Disease
Novo Nordisk A/S465 enrolled147 locationsNCT06717698
Recruiting
Phase 2
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Type 2 Diabetes Mellitus
Hoffmann-La Roche240 enrolled51 locationsNCT07112872
Recruiting
Phase 1
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Diabetes MellitusInsulin Sensitivity
Eli Lilly and Company95 enrolled1 locationNCT06982859
Recruiting
Phase 4
A Study of a Novel Precision Medicine Approach For Obesity
Obesity
Mayo Clinic135 enrolled2 locationsNCT06814938
Recruiting
Phase 4
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
ObesityChronic Kidney Disease
Western University, Canada60 enrolled1 locationNCT06396416
Recruiting
Phase 2
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
ObesityMuscle Loss
Actimed Therapeutics Ltd120 enrolled7 locationsNCT07101939